Velocity Clinical Research Executive and Leadership Team

George Carey, the Chief Executive Officer at Velocity Clinical Research, directs the overarching corporate strategy and long-term vision for the organization. By aligning clinical trial site capabilities with the evolving needs of biopharmaceutical customers, the Chief Executive Officer ensures consistent growth across North American markets. George Carey maintains direct oversight of executive leadership initiatives, fostering a culture of operational excellence and scientific integrity. This leadership role involves constant engagement with the Board to refine business models and expand the footprint of integrated research sites. Through the optimization of patient recruitment workflows, the Chief Executive Officer drives significant value for contract research organization partners. By prioritizing high-quality data collection and site performance, Carey secures the company's position as a premier partner in the global clinical research landscape, ultimately advancing the development of life-saving medical treatments through strategic resource allocation and organizational focus.

Mike Zaranek, the Chief Financial Officer at Velocity Clinical Research, manages the fiscal health and capital allocation strategies for the entire organization. Overseeing financial reporting, budgeting, and long-term investment planning, the Chief Financial Officer ensures the company maintains the necessary resources to scale clinical trial site operations effectively. Mike Zaranek directs the financial analysis of potential site acquisitions and infrastructure expansions, providing the data-driven insights required for sustainable growth. This leadership role involves close collaboration with the executive team to monitor revenue streams from biopharmaceutical partnerships and optimize cost structures across all research facilities. By implementing robust financial controls and risk management frameworks, Zaranek protects the company's assets while supporting aggressive market expansion. Through meticulous oversight of capital expenditures and cash flow management, the Chief Financial Officer sustains the financial stability required to support complex, multi-site clinical research programs on a national scale.

Robert Buynak, the Physician and President at Velocity Clinical Research, provides the medical leadership and clinical oversight necessary for high-quality trial execution. Overseeing the medical standards and scientific integrity of all research protocols, the Physician and President ensures that every site adheres to the highest clinical benchmarks. Robert Buynak directs the medical staff and principal investigators, fostering a culture of scientific excellence and patient safety. This leadership role involves collaborating with biopharmaceutical partners to ensure that trial designs are feasible and that patient populations are accurately identified. By bridging the gap between clinical research and medical practice, Buynak enhances the company's ability to deliver reliable data for drug development. Through the strategic oversight of medical quality assurance and protocol compliance, the Physician and President supports the company's reputation as a trusted partner in the clinical research industry, ensuring that all trials are conducted with precision and ethical rigor.

Kimberly Ballard, the Chief People Officer at Velocity Clinical Research, architects the human capital strategy required to support a vast network of clinical research professionals. Overseeing talent acquisition, employee development, and organizational culture, the Chief People Officer ensures the company attracts and retains the specialized expertise necessary for high-stakes clinical trials. Kimberly Ballard directs initiatives focused on workforce engagement and performance management, aligning individual contributions with the broader mission of accelerating medical research. This leadership role involves designing comprehensive training programs that maintain compliance and operational standards across all research sites. By fostering an inclusive and high-performance environment, Ballard drives organizational agility and employee retention. Through the implementation of modern HR technologies and strategic workforce planning, the Chief People Officer supports the company's ability to scale operations rapidly, ensuring that every site remains staffed with top-tier talent capable of delivering exceptional results for biopharmaceutical clients.

Brandi Lang, the Chief Legal Officer at Velocity Clinical Research, manages all legal affairs, regulatory compliance, and corporate governance matters. Overseeing the complex contractual landscape between the company, biopharmaceutical sponsors, and clinical trial sites, the Chief Legal Officer ensures adherence to stringent industry regulations and ethical standards. Brandi Lang directs the legal strategy for site acquisitions, intellectual property protection, and risk mitigation across all operational regions. This leadership role involves providing counsel to the executive team on legislative changes and industry-specific legal requirements that impact clinical trial execution. By establishing robust compliance frameworks, Lang safeguards the company's reputation and operational continuity. Through the proactive management of litigation risks and the negotiation of high-value partnership agreements, the Chief Legal Officer supports the company's strategic objectives. This focus on legal excellence ensures that all research activities remain compliant with federal and international standards, facilitating seamless collaboration with global research partners.

Nicholas Spittal, the Chief Operations Officer at Velocity Clinical Research, directs the daily execution of clinical trial site activities and operational workflows. Overseeing the performance of the integrated site network, the Chief Operations Officer ensures that patient recruitment, data integrity, and trial timelines meet the rigorous demands of biopharmaceutical customers. Nicholas Spittal architects scalable operational processes that allow the company to manage multiple complex studies simultaneously across diverse geographic locations. This leadership role involves coordinating with site directors and clinical staff to optimize resource utilization and maintain high standards of patient care. By implementing standardized operating procedures and performance metrics, Spittal drives efficiency and consistency throughout the organization. Through the continuous monitoring of site-level metrics and operational bottlenecks, the Chief Operations Officer ensures that all research facilities operate at peak capacity, ultimately supporting the company's mission to accelerate the delivery of new medical therapies to the market.